Van ECK Associates Corp Has $399.36 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• VanECK increased its Pfizer position by 1.7% in the second quarter, adding 283,767 shares to hold 16.58 million shares valued at approximately $399.4 million. Institutional investors collectively own 68.36% of Pfizer.
• Analyst sentiment remains mixed, with Pfizer receiving an overall “Hold” rating and an average price target of $28.28. Shares recently opened at $27.95, near their 52-week high of $28.75.
• Pfizer exceeded quarterly expectations with $0.77 EPS versus the $0.68 consensus and $15.03 billion in revenue, while maintaining a quarterly dividend of $0.43. However, its 6.2% yield and payout ratio above 100% continue to raise questions about dividend sustainability.

Van ECK Associates Corp boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,584,797 shares of the biopharmaceutical company's stock after buying an additional 283,767 shares during the period. Van ECK Associates Corp owned approximately 0.29% of Pfizer worth $399,362,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vermillion Wealth Management Inc. lifted its holdings in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 382 shares in the last quarter. Eagle Capital Management LLC raised its holdings in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after buying an additional 390 shares during the last quarter. Delta Financial Advisors LLC lifted its stake in shares of Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock valued at $709,000 after buying an additional 398 shares in the last quarter. Pines Wealth Management LLC grew its holdings in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company's stock valued at $235,000 after buying an additional 400 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD increased its position in shares of Pfizer by 1.0% during the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 400 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. JPMorgan Chase & Co. cut their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Finally, BMO Capital Markets dropped their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $28.28.

Pfizer Stock Performance

Shares of PFE stock opened at $27.95 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market cap of $159.31 billion, a price-to-earnings ratio of 36.78 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The firm's 50-day simple moving average is $25.55 and its two-hundred day simple moving average is $26.30.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer's payout ratio is presently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source